NVO Stock Recent News
NVO LATEST HEADLINES
Morning Brief anchor Julie Hyman breaks down the latest market news for August 18, 2025. Novo Nordisk's weight loss drug Wegovy is the first GLP-1 drug approved to treat liver disease.
PHILADELPHIA , Aug. 18, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo. Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the "Class Period"), may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Novo Nordisk A/S's FDA approval for Wegovy in MASH and aggressive Ozempic pricing boost its position, despite recent stock declines and competitive pressure from Eli Lilly and Company. Both NVO and LLY face regulatory headwinds from U.S. drug pricing demands, but I believe much of the bad news is already priced in for both. Novo's strategic pricing, strong clinical data, and attractive valuation make it my preferred long-term pick, though both stocks offer upside from current levels.
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy.
Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.
Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell due later in the week.
LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) have opportunity to lead the securities fraud class action lawsuit.
Novo Nordisk A/S NVO may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals.
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its Wegovy drug means for sales, and much more.